Navigation Links
Surveyed Neurologists Report Significantly Higher Relapsing-Remitting Multiple Sclerosis Patient Shares for Gilenya and Tysabri, Compared With One Year Ago
Date:12/12/2013

new products, notably Biogen Idec's Tecfidera, become available. Neurologists indicate that Aubagio will most likely compete with first-line products (i.e., Biogen Idec's Avonex, Bayer HealthCare's Betaferon and Teva's Copaxone), while Tecfidera may replace these products as well as Merck Serono's Rebif and Gilenya. Lemtrada, conversely, will most likely compete with Tysabri or would not replace an existing DMT, suggesting anticipated use as a last-line therapy.

"The European MS market is entering a dynamic period with two recent DMT launches and as many as six new DMTs launching in the next five years," said Decision Resources Group Senior Business Insights Analyst Georgiana L. Kuhlmann, S.M. "Our data find that gains for new brands will likely come at the expense of the interferon-beta therapies and Copaxone."

*Genzyme is a wholly-owned subsidiary of Sanofi.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients
2. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
3. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
4. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
5. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
6. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
7. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
8. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
9. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
10. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
11. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood instrumentation and consumables to the medical, research ... , Chairman and Chief Executive Officer, will present at ... Conference 2014 on Tuesday, September 9, 2014 at 12:30 ... Omni Berkshire Place Hotel in New York ...
(Date:8/29/2014)... Columbia and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") ... year-end financial statements.  The Company recently changed its fiscal ... an application to list its common stock on a ... DelMar,s financial statements as filed with the United ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Orthopedic Soft Tissue Repair Devices Market 2014-2018" ... tissues are the mass of cells that connect, support, ... soft tissues such as tendons, ligaments, cartilage, fascia, and ... degeneration of these tissues with age result in wear ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... (NASDAQ: STAA ), a leading developer, manufacturer and ... its presentation time at the 13 th Annual B. ... be on Wednesday, May 23, 2012 now ... Caldwell, President and CEO, will review the company,s recent financial ...
... 2012  Savvy vice presidents and directors across all ... organizational structures, critical activities, proven processes, and investment ... "In today,s increasingly competitive health ... have analysis from across the worldwide marketplace," says ...
Cached Medicine Technology:B. Riley Revises Timing of STAAR Surgical Presentation at Investor Conference 2Pharmaceutical Commercial Leaders Seek Global Benchmarks for More Informed Decision-Making 2
(Date:8/29/2014)... Daily Gossip reveals in its Stop Sciatica in 8 Minutes ... curing this disease. , The program promises to be ... only one week. This is described as a unique way ... , Moreover, with this new method patients might be ... just 8 minutes. , Interested customers can check the ...
(Date:8/29/2014)... The new review that can be read on DailyGossip.org ... that will permanently eliminate the symptoms of this disease. , ... a cure in as fast as 30 to 60 days. ... one week. , The Tinnitus Miracle review indicates that ... hearing loss, pain in the ear and dizziness. Read the ...
(Date:8/29/2014)... August 29, 2014 Cosmetic Town ... industry’s most notable plastic surgeons with prospective patients. ... about cutting edge techniques in plastic and reconstructive ... contain the most reliable information for general readers, ... treatment.     , Cosmetic Town began featuring renowned cosmetic ...
(Date:8/29/2014)... August 29, 2014 The Nasal ... reveals that the new program is actually based ... method was created by a former nasal polyps ... overcome the disturbing problem. Manuel Richards suffered from ... this system. , Learn more about Manuel ...
(Date:8/29/2014)... FL (PRWEB) August 29, 2014 The ... anxiously awaited final rule (file code CMS–0052–P) today allowing ... using the 2011 Edition Certified EHR Technology (CEHRT) or ... Eligible Professionals (EPs) who have not been able to ... reporting period in 2014 can continue to use 2011 ...
Breaking Medicine News(10 mins):Health News:Stop Sciatica in 8 Minutes Review Exposes Steven Guo's Complete Sciatica Cure 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2
... , WASHINGTON , Jan. 13 Bradley C. ... A. Mrusek , a resident of Maineville, Ohio , pleaded guilty late ... R. Barrett in Cincinnati , the Justice Department and Internal Revenue ... wer e i n d icted ...
... is the key, say researchers working with mice , ... giving scientists a greater understanding of how a brain ... level and why some people are resistant to antidepressants. ... stressful life events -- cause the mental disorders. Antidepressants ...
... complete agenda for the Seventh International Chronic ... online at http://www.ctosummit.org/overview/agenda.html . The CTO ... technologies, research findings and new developments in ... optimize success in chronic total coronary occlusions. ...
... , ... and BioScience Laboratories, Inc. announced a formal partnership to provide fully integrated topical clinical ... a single source for outsourcing clinical trials. , ... Wareham, MA (PRWEB) January 13, 2010 -- Synomics Pharma ...
... ... Hepregen’s Previous NIH Funding and Continued Development of the Company’s Platform for Advanced Toxicity ... ... Corporation, a leading provider of bioengineered solutions for drug development, announced today that it ...
... N.H. , Jan. 13 Eleme Medical Inc., ... announced today that they will be conducting a global contest ... of SmoothShapes . An alternative to celebrity endorsement, the campaign,s ... real women who experienced SmoothShapes cellulite and BodySlimming™ treatments, letting ...
Cached Medicine News:Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News:Chronic total occlusion strategies will be discussed during national summit February 4-5 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 3Health News:Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum 2Health News:Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum 3Health News:Eleme Medical Announces The Real Women of SmoothShapes(R) Campaign 2Health News:Eleme Medical Announces The Real Women of SmoothShapes(R) Campaign 3
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Medicine Products: